The same study shows that NRAS+ nor BRAF+ was associated with overall melanoma-specific survival, but the risk of death was significantly more reduced for higher-risk NRAS+ or BRAF+ (T2 or higher stage) [2]. This evidence concerns the gene BRAF and melanoma.